Advertisement

Cardiovascular Outcome Profiles of Anti-Diabetes Medications

  • Rekha B. KumarEmail author
Chapter

Abstract

A 71-year-old male with a 15-year history of type II diabetes and coronary artery disease who had one stent placed 3 years ago presents to his primary care doctor for management of obesity prior to knee replacement surgery. The patient is advised that he should lose approximately 25–30 lbs prior to undergoing surgery. His current BMI is 39 kg/m2 with a height of 5′10 and weight of 270 lbs. He is on pioglitazone 45 mg and glimepiride 2 mg daily for his diabetes. He reports significant weight gain over the past decade, particularly after starting his current medicines. He tries to follow a 1700 kcal/day diet but finds that his blood sugar occasionally feels low although he is not checking his glucose frequently but eats granola bars when he feels this way. He often feels that his blood sugar drops overnight and needs to eat a snack at that time as well. His hemoglobin A1c is 8.3% and he has mild neuropathy.

Keywords

Anti-diabetes medication Coronary artery disease Hypoglycemia Sulfonylurea Metformin 

References

  1. 1.
    Rita R. Kalyani et al. ADA’s Professional Practice Committee. Summary of revisions: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(Supplement 1):S4–6.Google Scholar
  2. 2.
    Cefalo W, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2018;41(1):14–31.CrossRefGoogle Scholar
  3. 3.
    Singh AK, Singh R. Recent cardiovascular outcome trials of antidiabetic drugs: a comparative analysis. Indian J Endocrinol Metab. 2017;21(1):4–10.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Comprehensive Weight Control Center, Division of EndocrinologyDiabetes and Metabolism, Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations